Dasgupta B, Duke O, Kyle V, Macfarlane D G, Hazleman B L, Panayi G S
Rheumatology Unit, UMDS, Guy's Hospital, London.
Ann Rheum Dis. 1987 Oct;46(10):746-9. doi: 10.1136/ard.46.10.746.
Serum specimens from 35 patients with polymyalgia rheumatica and giant cell arteritis (PMR/GCA) were obtained sequentially at variable time intervals up to a year from onset of disease. These were tested for antibodies to intermediate filaments by indirect immunofluorescence using HEp2 cells as substrate. Twenty four of 35 (68%) patients' sera at onset of disease were positive at an anti-intermediate filament antibody (AIFA) titre of greater than 1/40 compared with three outs of 19 (15%) control sera. AIFA were predominantly of IgM class, and there was no significant change in AIFA titres on follow up despite clinical remission of disease.
从35例风湿性多肌痛和巨细胞动脉炎(PMR/GCA)患者中获取血清标本,在疾病发作后的长达一年的不同时间间隔内依次采集。以人喉上皮癌细胞(HEp2细胞)为底物,通过间接免疫荧光法检测这些标本中的中间丝抗体。与19份对照血清中的3份(15%)相比,35例患者中有24例(68%)在疾病发作时血清抗中间丝抗体(AIFA)滴度大于1/40呈阳性。AIFA主要为IgM类,尽管疾病临床缓解,但随访时AIFA滴度无显著变化。